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874Objective: The internal thoracic artery is the gold standard conduit in coronary artery bypass grafting. Although
the right and left internal thoracic arteries are excellent conduits, the use of the bilateral internal thoracic artery is
not widespread. A recent report of the Society of Thoracic Surgery revealed that only a small percentage of
patients receive a bilateral internal thoracic artery in North America. The aim of this study was to determine
the current use of the bilateral internal thoracic artery during coronary artery bypass grafting among cardiac sur-
geons in Canada and identify the main concerns that limit the use of these conduits.
Methods:We developed an online survey with 17 questions about the use of the bilateral internal thoracic artery
in different clinical scenarios. An invitation to participate was sent to all the adult cardiac surgeons currently in
practice in Canada.
Results: A total of 101 surgeons (69%) of 147 currently in practice across 27 different hospitals completed the
survey. Forty percent of surgeons use the bilateral internal thoracic artery only sometimes (6%–25% of cases),
37% of surgeons use the bilateral internal thoracic artery very infrequently (<5% cases), 16% of surgeons use
the bilateral internal thoracic artery often (26%–50%), and only 7% of surgeons use the bilateral internal tho-
racic artery very often (>50%). The most common concerns in the use of the bilateral internal thoracic artery are
the risk of sternal wound infection and the unknown superiority of the right internal thoracic artery over other
conduits.
Conclusions: The majority of Canadian cardiac surgeons consider few clinical features, such as insulin-
dependent diabetes mellitus or morbid obesity, as contraindications to the use of bilateral internal thoracic artery.
However, the reported use of the bilateral internal thoracic artery is low. Awider diffusion of this technique is
warranted to improve the results of coronary surgery. (J Thorac Cardiovasc Surg 2012;144:874-9)The internal thoracic artery (ITA) is considered the gold
standard conduit in coronary artery bypass grafting
(CABG). The use of the left internal thoracic artery
(LITA) to bypass the left anterior descending artery has
been associated with improved survival at 10 years and a re-
duced incidence of myocardial infarction, cardiac events,
and reoperation compared with the use of vein grafts
alone.1,2 Surgeons have proposed that the use of bilateral
internal thoracic arteries (BITAs) would further improve
the long-term outcomes of coronary revascularization.
This hypothesis has been supported by recent clinical stud-
ies demonstrating improved survival and decreased reinter-
vention with BITA grafting compared with single ITAe Division of Cardiac Surgery, University of Ottawa Heart Institute, Ottawa,
io, Canada.
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The Journal of Thoracic and Cardiovascular Surguse.3-5 Moreover, angiographic studies have revealed
a long-term patency rate of the right ITA (RITA) to be
equivalent to the LITA and superior to the radial artery
and the saphenous vein grafts.6 However, this strategy has
not been universally accepted because of skepticism of
the degree of the incremental benefit and the perceived in-
creased risks of BITA grafting, such as sternal wound com-
plications.7-10 A recent analysis of the Society of Thoracic
Surgeons Database revealed that BITA grafting is used in
a small percentage of patients undergoing CABG in the
United States.11 In Great Britain, BITA use seems to be
only slightly more common.12
We discuss the current use of BITA grafting among car-
diac surgeons in Canada during CABG surgery and identify
the main concerns and perceptions that limit the use of this
strategy.MATERIAL AND METHODS
A questionnaire was developed to assess the use of BITAs during CABG
among Canadian cardiac surgeons. The survey consisted of 17 questions
relating to the use of BITAs in different clinical scenarios. Surgeons
were asked to indicate how often they use BITAs and to identify concerns
and limiting factors to a widespread use of these arterial conduits. The text
of the questionnaire is available in the Appendix.ery c October 2012
FIGURE 1. Stratification of responding surgeons according to the per-
centage of cases in which they use BITAs. BITA, Bilateral internal thoracic
artery.
Abbreviations and Acronyms
BITA ¼ bilateral internal thoracic artery
BMI ¼ body mass index
CABG ¼ coronary artery bypass graft
COPD ¼ chronic obstructive pulmonary disease
ITA ¼ internal thoracic artery
LITA ¼ left internal thoracic artery
RITA ¼ right internal thoracic artery
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accuracy of the list was confirmed by cross-referencing it to online data-
bases such as CTSNet, university and hospital websites, and e-mails to pro-
gram directors and division chiefs. The final list consisted of 147 surgeons.
The survey was developed as an online tool in a user-friendly format. A
link to the online survey was e-mailed to all practicing cardiac surgeons in
Canada. Pediatric cardiac surgeons were excluded from the study. Each
surgeon was assigned a unique log-in that allowed completing the survey
only once. The survey was completed online through a secure Web page.
Statistical analysis was performed using chi-square tests to compare fre-
quencies of categoric variables.
RESULTS
A total of 147 surgeons received the invitation to partic-
ipate in our survey. To increase the response rate, surgeons
who did not complete the survey within 1 month from the
first e-mail were contacted again by e-mail, fax, or tele-
phone. Eighty-five surgeons received a second invitation,
84 surgeons received a third invitation, 73 surgeons re-
ceived a fourth invitation, and 69 surgeons received a fifth
invitation. Thirty-eight surgeons were also contacted by
phone 1 time, 24 surgeons were contacted by phone 2 times,
23 surgeons were contacted by phone 3 times, and 21 sur-
geons were contacted by phone 4 times. Finally, 101 sur-
geons (69%) of 147 adult cardiac surgeons currently in
practice in Canada across 27 different cardiac surgery units
completed the survey. Thirty-nine percent of respondents
were in practice less than 10 years, 33% of respondents
were in practice for 11 to 20 years, and 28% of respondents
were in practice for more than 20 years.
The reported use of BITAs in isolated multivessel CABG
operations is shown in Figure 1. There was no difference in
the routine use of BITAs between young surgeons (in
practice<10 years, group A) and senior surgeons (in prac-
tice>10 years, group B): Some 77% of group A use BITAs
only sometimes or infrequently (infrequent users< 25%
or< 5% of cases) versus 71% of group B, and 23% use
BITAs often or very frequently (frequent users> 25% or
> 50% of cases) in group A versus 29% of group B
(P ¼ .64).
The single main factor influencing BITA use was the risk
of sternal wound infection in 35% of surgeons, the limited
length of the RITA in 28% of surgeons, the perceived lack
of confidence of the superiority of the RITA over saphenousThe Journal of Thoracic and Cavein or radial artery in terms of long-term outcome in 30%
of surgeons, and increased operative time or bleeding in 6%
of surgeons. The 2 groups of surgeons showed significantly
different (P ¼ .01) main concerns to the use of BITAs
(Table 1), with sternal wound infection the most common
concern for group A, whereas the unknown long-term supe-
riority of RITA over other conduits is most common in
group B. However, there was a similar prevalence of main
concerns to the use of these conduits between frequent
and infrequent users of BITAs (P ¼ .35). The distribution
of frequent users and infrequent users according to each
hospital is shown in Figure 2.
We then presented a clinical scenario with a hypothetical
patient undergoing CABG varying the clinical conditions to
isolate perceptions related to specific patient variables as
they related to BITA use. When asked about the age cutoff
to BITA use, there was no statistically significant difference
between frequent users and infrequent users for male pa-
tients but a trend toward the use of BITAs even in elderly
patients among frequent users (P ¼ .09). There was no sta-
tistically significant difference for the age cutoff to the use
of BITAs for female patients between infrequent and fre-
quent users (P ¼ .19).
The majority (80%) of respondents did not consider ac-
tive smoking a limiting factor for the use of BITAs. Half of
the respondents did not consider diabetes a limiting factor,
29% of the respondents considered insulin-dependent dia-
betes a contraindication, and 21% of the respondents did
not consider any form of diabetes a contraindication. A sig-
nificantly higher proportion of frequent users (55%) did not
consider diabetes a limitation to the use of BITAs compared
with infrequent users (47%) (P<.05). Furthermore, 60%
of surgeons would not consider the use of BITAs in patients
with a body mass index (BMI) more than 30, whereas 27%
did not consider obesity a limiting factor. Among frequent
users, 35% did not consider obesity a limiting factor,
whereas 20% of infrequent users did; however, this differ-
ence was not statistically significant (P ¼ .25).
Ninety percent of surgeons would consider BITAs in the
setting of a recent (<2 weeks) acute coronary syndrome, butrdiovascular Surgery c Volume 144, Number 4 875
TABLE 1. Prevalence of common concerns to bilateral internal
thoracic artery use among young surgeons (<10 years in practice,
group A) and senior surgeons (>10 years in practice, group B)
(P ¼ .01)
Main concern
Group A
n ¼ 40
Group B
n ¼ 61
Sternal wound infection 51% 24%
Reduced length of RITA 23% 31%
Unknown superiority of RITA over
other conduits
16% 40%
Operative time 10% 3%
Bleeding 0% 2%
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vere ejection fraction reduction (ejection fraction<30%).
In 45% of surgeons, the presence of ventricular dysfunction
is not a contraindication to the use of BITAs.
In patients with chronic obstructive pulmonary disease
(COPD), 44% consider this disease a contraindication to
the use of BITAs if the forced expiratory volume in 1 second
is less than 50% of the predicted value. In 21% of surgeons,
any degree of COPD is a contraindication to the use of
BITAs, whereas in 18% of surgeons, COPD is not consid-
ered a factor in this decision. In the presence of poor coro-
nary targets, the surgeons are almost equally distributed
between those who would use BITAs (47%) and those
who would not (53%).
The final section of the survey addressed technical ques-
tion regarding the use of BITAs. In patients with good cor-
onary targets, the preferred target for the RITA is the left
circumflex artery for 56% of respondents, the right coro-
nary artery for 34% of respondents, and the left anterior de-
scending for 10% of respondents. The technique of choice
for BITA harvesting is non-skeletonized in 56% and skele-
tonized in 27% of respondents. Although skeletonization
technique is more frequent among frequent users (37%)FIGURE 2. Distribution of frequent users and in
876 The Journal of Thoracic and Cardiovascular Surgthan infrequent users (20%), the difference was not statisti-
cally significant (P ¼ .28). The rationale that influences the
technique of choice is a perceived reduced risk of injury to
the ITA with the non-skeletonization for 33% of respon-
dents, a perceived reduced risk of chest wall injury or infec-
tion with skeletonization for 15% of respondents,
a perceived longer conduit length with skeletonization for
25% of respondents, and a perceived reduced operative
time with non-skeletonization for 10% of respondents. Fi-
nally, in case of insufficient length of the RITA in situ to
reach the coronary target, 89% of surgeons would use the
RITA as a free or composite graft.DISCUSSION
This survey was completed to delineate perceptions
among Canadian cardiac surgeons that influence the use
of BITAs. We demonstrated that although Canadian sur-
geons consider relatively infrequent clinical features as ab-
solute contraindications to BITA use (eg, insulin-dependent
diabetes mellitus, BMI>30 or age>70 years), the majority
(76%) still report using BITAs in only a minority of cases
(<25%).
There is strong clinical evidence that BITA use results in
improved long-term outcomes. BITA use has been associ-
ated with lower 30-day mortality and a reduced incidence
of death, reoperation, and coronary angioplasty at 10 and
15 years postoperatively compared with single ITA
use.5,13,14 This concept is further supported by the results
of 2 recent meta-analyses15,16 comprising 9 studies with
more than 15,000 patients, both showing a significant
improvement of survival for the BITA group compared
with the single ITA. However, a recent analysis of the
Society of Thoracic Surgeons’ database revealed that in
more than 541,000 patients undergoing operations in 745
hospitals across the United States between 2002 and
2005, only 4% of patients received BITA grafts.11frequent users according to hospital response.
ery c October 2012
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less than 10% received BITA. In 54.6% of US hospitals
participating in the database, BITA use was less than 2%
and 11.4% of units did not use BITAs at all. Of note, there
was no correlation between BITA use and hospital volume.
In contrast, the Sixth National Adult Cardiac Database
Report of the Society for Cardiothoracic Surgery of Great
Britain and Ireland revealed that in more than 114.300 iso-
lated CABG operations, 15% of patients received 2 arterial
grafts (not specifying if the second graft was the RITA or
others).12 We can argue that the percentage of BITA use
is then also lower than this and that this percentage seems
to have changed little since 2002. Patients who received 2
arterial grafts were more likely to be at low surgical risk:
usually aged less than 65 years, mainly male, and with
BMI less than 25, no diabetes, and good LV function. In
the recent SYNTAX Trial, despite a mean age of 65 years
and a study protocol encouraging the use of arterial grafts,
only 22.7% of patients received BITA.17
The most common concerns among Canadian surgeons
regarding the use of BITAs are the risk of sternal wound in-
fection, the limited length of RITA, and the unknown supe-
riority of RITA over other conduits. Younger surgeons are
usually more concerned about the risk of sternal complica-
tions, whereas more experienced surgeons are more con-
cerned about the results of RITA over other conduits, such
as radial artery or saphenous vein.
Several studies have shown an increased risk of sternal
wound infection with BITAs, especially in diabetic patients,
with a relative risk of 3.2 times (BITAvs single ITA).18 This
increased risk has to be balanced in daily practice with the
potential benefits of BITA, particularly in diabetic patients
who show a reduced patency rate of vein grafts in the
long term. The skeletonization technique, although techni-
cally more laborious, has been associated with a decreased
risk of sternal complications, particularly in diabetic pa-
tients,7,19-22 decreased chest wall pain, and improved
sternal perfusion.23
In the current survey, it was demonstrated that the major-
ity of surgeons would consider RITA as a free or composite
graft. This strategy is consistent with the literature support-
ing the use of this conduit as a composite graft connected
proximally to the LITA and distally to the left coronary
system.24
Common objections to the use of BITA, such as active
smoking, recent acute coronary syndrome, or COPD, are
not considered absolute contraindications to the use of
BITAs among the majority of surgeons. Furthermore, fre-
quent users of BITA among Canadian surgeons seem to
be also more ‘‘liberal’’ compared with the infrequent users
in terms of their indications. Indeed, they usually report
a higher cutoff for the use of BITAs in terms of age for
both male and female patients, grade of obesity, type of di-
abetes, and class of ventricle. Despite this, frequent usersThe Journal of Thoracic and Caare usually more concerned about wound infection and
thus more often harvest the BITA with the skeletonization
technique.
Although the majority of surgeons would consider the
use of BITAs aggressively, this perception is discordant
with the current practice in North America whereby the
use of BITAs remains restricted.Study Limitations
These data represent the results of a voluntary participa-
tion to an online questionnaire and are subject to a number
of limitations. Answers were not verified for accuracy. Al-
though every effort was made to maximize the response
rate, 31% of Canadian cardiac surgeons did not participate
in the survey. It is possible that the current practice of these
surgeons could significantly differ from the surgeons who
participated in the survey.CONCLUSIONS
Numerous studies have shown the benefit of BITAs in
terms of long-term graft patency and patient survival. How-
ever, the use of BITAs still seems to be low among cardiac
surgeons in Canada. The most common concern that limits
the use of BITA is the risk of sternal wound infection. The
risk of wound infection or other complications should be
balanced with the long-term benefit of 2 arterial grafts.
The perceptions reflected will serve as an excellent founda-
tion to validate the equipoise of supporting a prospective
trial assessing the value of BITA grafting during coronary
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185-90.APPENDIX 1. Text of the online bilateral internal
thoracic artery survey
Dear colleague,
We invite you to participate in a survey about the use of
bilateral internal thoracic arteries (BITAs) during coronary
surgery in Canada. The survey will take approximately 10
minutes to complete.
It is recognized that bypass of the left anterior descending
artery with the left internal thoracic artery (LITA) is the key
factor responsible for the survival advantage of coronary
surgery compared with medical therapy and stenting.
Many have advocated that concomitant use of the right in-
ternal thoracic artery (RITA) may further improve clinical
outcomes. There are little data on the prevalence of BITA
use among Canadian cardiac surgeons.
When answering the following questions and clinical
scenarios, please assume the following: 1) elective or urgent
(in-house – waitlist> 24 hours) cases with hemodynamic
stability (non-emergency); 2) isolated coronary surgery878 The Journal of Thoracic and Cardiovascular Surg(no major concomitant procedures, eg, valve, aortic,
aneurysm); 3) all possible conduits available (eg, no vein
stripping, radial artery not previously cannulated); 4) as-
cending aorta nondiseased such that on pump surgery and
traditional proximal anastomoses feasible
Question 1. How many years have you been in practice
as a staff cardiac surgeon? A:<5 years, B: 6–10 years, C:
11–15 years, D: 16–20 years, E:>21–25 years, F:>25
years.
Question 2. In your opinion, which issue limits the use of
BITA in current practice? Select all that apply. A: the risk of
superficial/deep sternal wound infection; B: increased oper-
ative time; C: the limited length of RITA; D: unknown su-
periority of RITA over saphenous vein or radial artery in
terms of long-term outcome.
Question 3. In your current practice, how often do you
use both the left and right internal thoracic arteries
(BITA) as conduits in isolated multivessel CABG? A:
very frequently (>50% of cases); B: often (26%–50%);
C: sometimes (6%–25%); D: very infrequently (<10%).
Question 4. In an otherwise healthy patient (nonsmoker,
no diabetes, no obesity, normal left ventricular (LV) func-
tion, good coronary target), male gender, what age cutoff
would you not use BITA? A:>50 years; B:>60 years; C:
>70 years; D:>80 years; E: Age is not a limiting factor.
Question 5. In an otherwise healthy patient (nonsmoker,
no diabetes, no obesity, normal LV function, good coronary
target), female gender, what age cutoff would you not use
BITA? A:>50 years; B:>60 years; C:>70 years; D:>80
years; E: Age is not a limiting factor.
Question 6. In your practice, do you consider active
smoking (>0.5 packs/day) a contraindication to the use of
BITA in a patient who would otherwise be a candidate re-
gardless of age or other factors? A: Yes, I would not con-
sider BITA; B: No, I would still consider BITA.
Question 7. In an otherwise healthy patient, young
(aged<50 years), nonsmoker, no obesity, normal LV func-
tion, good coronary targets, would diabetes be a limiting
factor for the use of BITA? A: only insulin-dependent dia-
betes (IDDM); B: with orally treated diabetes (non-
IDDM) or IDDM; C: any diabetes would be; D: Diabetes
is not a limiting factor.
Question 8. In an otherwise healthy patient (young
[aged<50 years, nonsmoker, no obesity, normal LV func-
tion, good coronary targets), would diabetes be a limiting
factor for the use of BITA? A: if the patient is overweight
(BMI>25); B: only if the patient is severely obese (BMI
>30); C: Obesity is not a limiting factor.
Question 9. In an otherwise healthy patient (young, non-
smoker, no diabetes, no obesity, normal LV function, good
coronary targets) would a recent acute coronary syndrome
(<2 weeks) as an isolated risk factor be a limiting factor
for considering the use of BITA? A: Yes, I would not use
BITA; B: No, I would still consider BITA.ery c October 2012
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smoker, no diabetes, no obesity, good coronary targets),
would LV dysfunction be a limiting factor for considering
the use of BITA? A: always; B: only if ejection fraction
(EF) is< 50%; C: only if EF is< 40%; D: only if EF
is<30%; E: LV dysfunction is not a limiting factor.
Question 11. In an otherwise healthy patient (young, no
diabetes, no obesity, good coronary targets) is chronic ob-
structive pulmonary disease (COPD) a contraindication for
the use of BITA? A: always; B: only if forced expiratory
volume in 1 second (FEV1) is< 75% predicted; C: only
if FEV1 is< 50% predicted; D: COPD is not a limiting
factor.
Question 12. In an otherwise healthy patient (young,
nonsmoker, no diabetes, no obesity, normal LV), are poor
coronary targets (small vessels, diffuse disease) a contrain-
dication to the use of BITA? A: Yes, I would not use BITA;
B: No, I would still consider BITA.
Question 13. In an otherwise healthy patient (young, non-
smoker, no diabetes, no obesity, normal ventricle) with
triple-vessel disease and good coronary targets, what is
your preferred target for the RITA? A: right coronary artery;
B: left circumflex artery; C: left anterior descending.The Journal of Thoracic and CaQuestion 14. Which is your preferred harvesting tech-
nique for BITA? A: non-skeletonized; B: skeletonized; C:
1 non-skeletonized, 1 skeletonized; D: other.
Question 15. What factors influence on your preferred
harvesting technique? Select all that apply. A: increased
length with skeletonized; B: reduced operative time with
non-skeletonized; C: reduced infection with skeletonized;
D: reduced chest wall injury with skeletonized; E: improved
ITA flowwith skeletonized; F: reduced ITA injury with non-
skeletonized.
Question 16. If the length of the RITA in situ is not
enough to reach the preferred target, would you use the
RITA as a free graft or composite graft? A: Yes, I would
use the RITA as a free graft; B: Yes, I would use the
RITA as a composite graft; C: Yes, I would use the RITA
as a free or composite graft; D: No, I would not use the
RITA as a free or composite graft.
Question 17. In your practice, which is the most impor-
tant issue that limits the use of BITA? Select only one. A:
the risk of superficial/deep sternal wound infection; B: in-
creased bleeding; C: increased operative time; D: unknown
superiority of RITA over saphenous vein or radial artery in
terms of long-term outcome; E: limited length of RITA.rdiovascular Surgery c Volume 144, Number 4 879
